Several media have reported on the collaboration of Nostrum Biodiscovery, a company cofounded by IRB Barcelona researcher Modesto Orozco, with Grifols and IrsiCaixa. This spin-off company from IRB Barcelona will contribute to research into COVID-19 by providing data that will facilitate the intelligent design of drugs in silico for the treatment of coronavirus.
The company has issued a press release to announce this collaboration and the appointment of its new CEO, Ezequiel Mas del Molino. Nostrum Biodiscovery thus begins a new period marked by an ambitious growth plan in which it will strengthen its present in the European and US markets.
Link to: Expansión
Link to: Europa Press
Link to: Siglo XXI
Link to: La Vanguardia
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to offer pioneering solutions to unresolved medical needs in cancer and other diseases related to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).